Expert Outlook: Zoetis Through The Eyes Of 4 Analysts
Portfolio Pulse from Benzinga Insights
Zoetis (NYSE:ZTS) received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for ZTS has been raised to $225.25, reflecting a 2.97% increase from the previous target. Analysts from Stifel, Piper Sandler, Barclays, and Goldman Sachs have adjusted their ratings and price targets, indicating a positive outlook on Zoetis's performance. The company, a leader in animal health products, has shown strong financial indicators such as revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio and market capitalization below industry average.
April 02, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zoetis has received mixed analyst ratings with a recent trend towards bullishness. The average 12-month price target has increased to $225.25. Financially, Zoetis shows strong performance with notable revenue growth and profitability metrics, although it has a high debt-to-equity ratio.
The increase in the average price target and positive adjustments in analyst ratings suggest a bullish outlook for Zoetis. Strong financial indicators such as revenue growth, net margin, ROE, and ROA support this positive sentiment, although the high debt-to-equity ratio is a concern. The overall analysis indicates a likely positive short-term impact on ZTS's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100